Opioids remain the drugs of choice for the treatment of severe pain. In recent years several
new potent opioids have become available for clinical use. These newer drugs are generally …

The traditional view of opioids held that the individual opioid agonists shared the same
mechanism of action, differing only in their potency and pharmacokinetic properties …

In the last two decades, opioid analgesics have assumed an important place in general
anesthetic practice in the United States. Part of the reason for this has been the introduction …

Background There are a number of false myths about buprenorphine based on unconfirmed
animal data, even from isolated animal organs, and early clinical research. These myths …

In contrast to other opioids, fentanyl and buprenorphine share a number of physicochemical
properties that render both agents potentially suitable for transdermal delivery. However …

Opioids produce analgesia but also respiratory depression, dependence and a variety of
other troublesome side effects. With this in mind, several alternatives to opioids in the …

Objective An expert panel convened to reach a consensus on common misconceptions
surrounding buprenorphine, a Schedule III partial µ-opioid receptor agonist indicated for …

The agonist-antagonist opioid analgesics are a heterogeneous group of drugs with
moderate to strong analgesic activity comparable to that of the pure agonist opioids such as …

What is known and objective Based on in vitro assays and select animal models,
buprenorphine is commonly called a 'partial agonist'. An implication is that it should produce …

Abstract Purpose of Review The purpose of this review is to evaluate and explain our current
understanding of the clinical use of buprenorphine in the treatment of chronic pain. Recent …